Picture: AFP
Researchers leading a clinical trial testing the efficacy of anti-malarial
drug hydroxychloroquine will proceed with administering it to Australian
coronavirus patients after international studies challenging the drug’s
efficacy and safety were questioned.
The resumption of trials followed revelations that data relied on
by scientific journals The Lancet and the New England Journal of Medicine was
based on flawed data from a little-known US healthcare analytics company.
No comments:
Post a Comment